FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.
What happened
FDA reached this finding by reviewing records the firm submitted after FDA's January 20, 2026 request for records under section 704(a)(4) of the Food, Drug, and Cosmetic Act; there was no inspection. FDA said the firm does not test each batch of finished drug product before release, including no sterility testing on products labeled "sterile," has no process validation procedures or studies, and its quality unit did not do its job. On October 21, 2026 FDA recommended a recall of all lots labeled sterile within expiry, and the firm agreed on October 22, 2026.
What FDA found
The firm did not test each batch of finished drug before release to confirm the identity and strength of the active ingredient, and did not test for objectionable microorganisms.
21 CFR 211.165(a) and 211.165(b)The firm did not perform sterility testing on drug products that it labels as sterile.
21 CFR 211.165(b)The firm had no written procedures for production and process control and had done no process validation studies, including none to show its process can make a sterile product.
21 CFR 211.100(a)The quality unit did not ensure adequate laboratory control procedures to confirm identity, strength, quality and purity of the drugs.
21 CFR 211.22 and 211.160(b)The quality unit did not set up an adequate ongoing stability program.
21 CFR 211.22 and 211.166(a)
What FDA wants
Send a written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receiving the letter, marked with FEI 3013504845 and ATTN: Rory Geyer. FDA also recommends engaging a qualified CGMP consultant to run a six-system audit before the firm seeks resolution of its compliance status.
Who should pay attention
- U.S. distributors and retailers selling OTC drugs labeled sterile from this firm
- importers and U.S. agents handling shipments from this manufacturer
- brands and buyers sourcing OTC drug products from Chinese manufacturers
This is a summary. Read the original letter on fda.gov.